The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01685008
Recruitment Status : Completed
First Posted : September 13, 2012
Results First Posted : November 7, 2023
Last Update Posted : November 7, 2023
Sponsor:
Information provided by (Responsible Party):
MorphoSys AG

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an open-label, multicenter study to characterize the safety and efficacy of the human anti-CD19 antibody MOR00208 in adult patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) who have received at least 1 prior therapy containing rituximab (at least once).

Condition or disease Intervention/treatment Phase
Non-Hodgkin Lymphoma Drug: MOR00208 (formerly Xmab 5574) Phase 2

Detailed Description:
The study enrols patients from four different NHL subtypes: follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other indolent NHL (iNHL). The study will employ a two-stage design where the decision to further enrol any NHL subtype in stage 2 will depend on best responses after two or three cycles in stage 1.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 92 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIa, Open-label, Multicenter Study of Single-agent MOR00208, an Fc-optimized Anti-CD19 Antibody, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Actual Study Start Date : April 23, 2013
Actual Primary Completion Date : April 6, 2022
Actual Study Completion Date : April 6, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: MOR00208 (formerly Xmab5574)
intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody
 Drug: MOR00208 (formerly Xmab 5574)
Other Name: MOR208


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: From first dose until Follow-up Visit 12, up to 4.5 years ]
    Proportion of patients with Complete Remission (CR; disappearance of all evidence of disease) or Partial Remission (PR; regression of measurable disease and no new sites), assessed as per the 2007 International Working Group (IWG) response criteria by radiographic evaluations (CT, PET, MRI, or other).


Secondary Outcome Measures :
  1. Stable Disease (SD) Rate [ Time Frame: From first dose until Follow-up Visit 12, up to 4.5 years ]
    Proportion of patients with Stable Disease (failure to attain CR/PR with no progressive disease)

  2. Duration of Response (DoR) [ Time Frame: From first dose until Follow-up Visit 12, up to 4.5 years ]
    Time from first CR or PR to first documentation of relapse/progression (any new lesion or increase by ≥ 50% of previously identified site)

  3. Time to Progression (TTP) [ Time Frame: From first dose until Follow-up Visit 12, up to 4.5 years ]
    Time from first dosing until documentation of progression or death due to lymphoma

  4. Progression-free Survival (PFS) [ Time Frame: From first dose until Follow-up Visit 12, up to 4.5 years ]
    Time from first dosing until progression or death due to any case

  5. Incidence and Severity of Adverse Events (AEs) [ Time Frame: From first dose until 30 days after last dose of MOR00208, up to 8.5 years ]
    Number of patients with treatment-emergent AEs rated Mild, Moderate, and Severe

  6. Number and Proportion of Patients Who Potentially Developed Anti-MOR00208 Antibodies and Semiquantitative Anti-MOR00208 Antibody Assessments [ Time Frame: From first dose until Follow-up Visit 3, up to 7 months ]
    Number of patients with at least one positive (+ve) post-Baseline sample containing positive anti-MOR00208 antibodies; Baseline (pre-dose) sample has to be tested negative (-ve)

  7. Pharmacokinetic (PK) Parameter: Maximum Serum Concentration Observed (Cmax) of MOR00208 [ Time Frame: Estimated from first dose (samples taken on first day of dosing at pre-dose, end of infusion, after 1 hour, 4 hours, 24 hours, and pre-dose on Day 8) ]
    The highest concentration of MOR00208 measured in serum

  8. PK Parameter: Time to Maximum Serum Concentration Observed (Tmax) of MOR00208 [ Time Frame: Estimated from first dose (samples taken on first day of dosing at pre-dose, end of infusion, after 1 hour, 4 hours, 24 hours, and pre-dose on Day 8) ]
    The time to highest concentration of MOR00208 measured in serum

  9. PK Parameter: Apparent Trough Serum Concentration Before Dosing (Clast) of MOR00208 [ Time Frame: Estimated from first dose (samples taken on first day of dosing at pre-dose, end of infusion, after 1 hour, 4 hours, 24 hours, and pre-dose on Day 8) ]
    The last quantifiable concentration from the first dose of MOR00208

  10. PK Parameter: Area Under the Concentration Curve From Dose Time Zero to the Time the Last Quantifiable Concentration is Observed (AUC[0-t]) of MOR00208 [ Time Frame: Estimated from first dose (samples taken on first day of dosing at pre-dose, end of infusion, after 1 hour, 4 hours, 24 hours, and pre-dose on Day 8) ]
    Area under the concentration curve. The time curve from time zero (0) to the time that the last concentration above the lower limit of quantification (LLQ) is observed.

  11. PK Parameter: Area Under the Concentration Curve From Dose Time Zero to Infinity (AUC[0-inf]) of MOR00208 [ Time Frame: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks]) ]
    Area under the concentration curve. The time curve from time zero (0) to infinity (inf), where infinity is computed from AUC0-t + [Ct/λZ)]. Ct is calculated from the concentration at the last sampling time at which the sample is above LLQ.

  12. PK Parameter: Apparent Terminal Rate Constant (λz) of MOR00208 [ Time Frame: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks]) ]
    Apparent terminal rate constant calculated from the regression analysis (slope) from the log-transformed measured concentrations on the terminal phase of the time-point concentration curve

  13. PK Parameter: Apparent Terminal Half-life (t[1/2]) of MOR00208 [ Time Frame: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks]) ]
    Apparent terminal half-life calculated from ln(2)/λz

  14. PK Parameter: Total Body Clearance (CL) of MOR00208 [ Time Frame: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks]) ]
    Total body clearance calculated for single or multiple doses: dose(s)/AUC(0-inf)

  15. PK Parameter: Apparent Volume of Distribution (Vz) of MOR00208 [ Time Frame: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks]) ]
    Apparent volume of distribution during the terminal phase, calculated from dose/(AUC(0-inf)*λz)

  16. Absolute Change From Baseline in Measurements of B-cell Populations [ Time Frame: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years) ]
    Actual change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: B-cell populations

  17. Percent Change From Baseline in Measurements of B-cell Populations [ Time Frame: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years) ]
    Relative change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: B-cell populations

  18. Absolute Change From Baseline in Measurements of T-cell Populations [ Time Frame: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years) ]
    Actual change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: T-cell populations

  19. Percent Change From Baseline in Measurements of T-cell Populations [ Time Frame: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years) ]
    Relative change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: T-cell populations

  20. Absolute Change From Baseline in Measurements of NK Cell Populations [ Time Frame: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years) ]
    Actual change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: NK cell populations

  21. Percent Change From Baseline in Measurements of NK Cell Populations [ Time Frame: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years) ]
    Relative change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: NK cell populations

  22. Evaluation of AEs Stratified by Baseline CD19 Expression on Malignant Lymphoma Cells [ Time Frame: From first dose until 30 days after last dose of MOR00208, up to 8.5 years ]
    Incidence of AEs as stratified by presence of CD19 on malignant lymphoma cells detected by tumor biopsy/aspirate during Screening

  23. Evaluation of ORR Stratified by Baseline CD19 Expression on Malignant Lymphoma Cells [ Time Frame: From first dose until Follow-up Visit 12, up to 4.5 years ]
    The analysis of the primary endpoint (ORR) will additionally be stratified by presence of CD19 on malignant lymphoma cells detected by tumor biopsy/aspirate during Screening

  24. Evaluation of AEs Stratified by FcγRIIa Polymorphism [ Time Frame: From first dose until 30 days after last dose of MOR00208, up to 8.5 years ]
    Incidence of AEs as stratified by FcγRIIa polymorphism subgroups (genotypes HH, HR, or RR)

  25. Evaluation of AEs Stratified by FcγRIIIa Polymorphism [ Time Frame: From first dose until 30 days after last dose of MOR00208, up to 8.5 years ]
    Incidence of AEs as stratified by FcγRIIIa polymorphism subgroups (genotypes FF, FV, or VV)

  26. Evaluation of ORR Stratified by FcγRIIa Polymorphism [ Time Frame: From first dose until Follow-up Visit 12, up to 4.5 years ]
    The analysis of the primary endpoint (ORR) will additionally be stratified by FcγRIIa polymorphism subgroups (genotypes HH, HR, or RR)

  27. Evaluation of ORR Stratified by FcγRIIIa Polymorphism [ Time Frame: From first dose until Follow-up Visit 12, up to 4.5 years ]
    The analysis of the primary endpoint (ORR) will additionally be stratified by FcγRIIIa polymorphism subgroups (genotypes FF, FV, or VV)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients ≥ 18 years of age.

  2. Histologically-confirmed diagnosis according to Revised European American Lymphoma/World Health Organization classification, of the following B-cell lymphomas:

    1. FL
    2. Other indolent NHL (eg, MZL/MALT)
    3. DLBCL
    4. MCL
  3. Patients' NHL must have progressed after at least 1 prior rituximab containing regimen.

  4. One site of measurable disease by magnetic resonance imaging (MRI) or computed tomography (CT) scan defined as at least one lesion that measures at least 1.5 × 1.5 cm.

    Exception:

    For patients with MCL only, patients with nonmeasurable disease but evaluable sites (bone marrow, spleen, peripheral blood, gastrointestinal tract) can be enrolled.

  5. Patients who have previously received an autologous stem cell transplantation must be at least 4 weeks post-transplant before study drug administration and must have exhibited a full haematological recovery.
  6. Discontinued previous monoclonal antibody therapy (except rituximab) or radioimmunotherapy administration for at least 60 days before study drug administration.
  7. Off rituximab for at least 14 days before the screening visit and be confirmed to have either no response or have disease progression after rituximab treatment.
  8. Patients with DLBCL had a positive [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at baseline (Cheson 2007 response criteria).
  9. Life expectancy of > 3 months.
  10. Eastern Cooperative Oncology Group (ECOG) performance status of < 3.

  11. Laboratory criteria at screening:

    1. Absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L
    2. Platelet count ≥ 75 × 10^9/L without previous transfusion within 10 days of first study drug administration
    3. Haemoglobin ≥ 8.0 g/dL (may have been transfused)
    4. Serum creatinine < 2.0 x upper limit of normal (ULN)
    5. Total bilirubin ≤ 2.0 × ULN
    6. Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN
  12. If a female of childbearing potential, a negative pregnancy test must be confirmed before enrolment and use of double-barrier contraception or oral contraceptive plus barrier contraceptive must be used during the study and for 3 months after the last dose, or confirmation of having undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation.
  13. If a male, an effective barrier method of contraception must be used during the study and for 3 months after the last dose if the patient is sexually active with a female of childbearing potential.
  14. Able to comply with all study-related procedures, medication use, and evaluations.
  15. Able to understand and give written informed consent and comply with the study protocol.

Exclusion Criteria:

  1. Previous treatment with cytotoxic chemotherapy, immunotherapy, radiotherapy or other lymphoma specific therapy within 14 days before the screening visit or patient has not recovered from side effects of previous lymphoma-specific therapy.
  2. Treatment with a systemic investigational agent within 28 days before the screening visit.
  3. Previous treatment with an anti-CD19 antibody or fragments.
  4. Previous allogenic stem cell transplantation.
  5. Known or suspected hypersensitivity to the excipients contained in the study drug formulation.
  6. Clinically significant cardiovascular disease or cardiac insufficiency, cardiomyopathy, preexisting clinically significant arrhythmia, acute myocardial infarction within 3 months of enrolment, angina pectoris within 3 months of enrolment.

  7. Patients with positive hepatitis serology:

    Hepatitis B (HBV): Patients with positive serology for HBV defined as positivity for hepatitis B surface antigen (HBsAg) or total anti-hepatitis B core antibody (anti-HBc). Patients positive for anti-HBc may be included if HBV DNA is not detectable.

    Hepatitis C (HCV): Patients positive HCV serology (defined as positive for anti-HCV antibody [anti-HCV]) unless HCV-ribonucleic acid (RNA) is confirmed negative.

  8. History of HIV infection.
  9. Any active systemic infection (viral, fungal, or bacterial) requiring active parenteral antibiotic therapy within 4 weeks of study drug administration.
  10. Current treatment with immunosuppressive agents other than prescribed corticosteroids (not more than 10-mg prednisone equivalent).
  11. Major surgery or radiation therapy within 4 weeks before first study drug administration.
  12. Systemic diseases (cardiovascular, renal, hepatic, etc) that would prevent study treatment in the investigator's opinion.
  13. History or clinical evidence of central nervous system (CNS), meningeal, or epidural disease, including brain metastasis.
  14. Active treatment/chemotherapy for another primary malignancy within the past 5 years (except for ductal breast cancer in situ, non-melanoma skin cancer, prostate cancer not requiring treatment, and cervical carcinoma in situ).
  15. Pregnancy or breastfeeding in women and women of childbearing potential not using an acceptable method of birth control.
  16. History of noncompliance to medical regimens or patients who are considered potentially unreliable not cooperative.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01685008


Locations
Show Show 26 study locations
Sponsors and Collaborators
MorphoSys AG
  Study Documents (Full-Text)

Documents provided by MorphoSys AG:
Study Protocol  [PDF] May 26, 2020
Statistical Analysis Plan  [PDF] April 3, 2019

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: MorphoSys AG
ClinicalTrials.gov Identifier: NCT01685008    
Other Study ID Numbers: MOR208C201
2012-002659-41 ( EudraCT Number )
First Posted: September 13, 2012    Key Record Dates
Results First Posted: November 7, 2023
Last Update Posted: November 7, 2023
Last Verified: October 2023
Keywords provided by MorphoSys AG:
NHL
CD19
MOR208
MOR00208
 Xmab5574
B-Cell Non-Hodgkin´s Lymphoma
Fc-optimized Anti-CD19 Antibody
Tafasitamab
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
 Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases